Lu Lu
Shandong University
12 Papers
4 Citations
Lu Lu is an academic researcher from Shandong University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Review: Application of chitosan and its derivatives in medical materials.
Wenjie Tang,Juan Wang,Huiwen Hou,Yan Li,Jie Wang,Jiaai Fu,Lu Lu,Didi Gao,Zengmei Liu,F. Zhao,Xinqing Gao,Peixue Ling,Fengshan Wang,Feng Sun,Haining Tan +14 more
TL;DR: The most extensive research has been conducted in the pharmaceutical field as discussed by the authors , which has shown that chitosan does not melt or dissolve in water, alkaline solutions and general organic solvents, which greatly limits its application range.
83
New insights into the role of co-receptor neuropilins in tumour angiogenesis and lymphangiogenesis and targeted therapy strategies.
TL;DR: This review introduced the schematic diagram to visually reveal the function of NRP1 and NRP2 in enhancing the binding affinity of VEGFR2 to VEGFA-165 and VEGfr3 to V EGFC, respectively and discussed the signalling pathways that depend on the co-receptors NRP 1 and N RP2.
32
Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer
Lu Lu,He Jian-Zhang,Yudong Zhou,Jia Yi Lin,Weidong Gao,Ting Yang,Jinmei Jin,Lijun Zhang,Dale G. Nagle,Weidong Zhang,Ye Wu,Hongzhuan Chen,Xin Luan +12 more
TL;DR: It is demonstrated that PEG-MP9-aPDL1-driven oncolysis induces a panel of immunogenic cell death (ICD)-relevant damage-associated molecular patterns (DAMPs) both in vitro and in vivo, which are key elements for immunotherapy with PD-L1 inhibitor.
17
Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
TL;DR: In this article , a peptide-drug conjugates (PDCs) strategy was used to improve the specificity and penetrability of paclitaxel (PTX) at the tumor site.
CD44 targeting nanodrug based on chondroitin sulfate for melanoma therapy by inducing mitochondrial apoptosis pathways.
Yan Li,Huiwen Hou,Zengmei Liu,Wen Tang,Jie Wang,Lu Lu,Jiaai Fu,Didi Gao,F. Zhao,Xinqing Gao,Peixue Ling,Fengshan Wang,Feng Sun,Haining Tan +13 more
TL;DR: A novel redox and acid sensitive nanodrug (CDDP-CS-Cys-EA, CCEA), composed of chondroitin sulfate (CS), antiangiogenic peptide (endostatin2-alft1, EA) and chemotherapeutic drug (cisplatin, CDDP), which exhibited strongAntiangiogenesis and antitumor characteristics in vitro.
14